Colorectal Cancer

Colorectal Cancer Screening: Major Communication Gap in the Clinical Setting

A study by researchers at the American Cancer Society investigating the prevalence of receiving a clinician recommendation...

Issues in Oncology

Retrospective Study Reports Tyrosine Kinase Inhibitor Used in CML Associated With Nephrotoxicity

Investigators reported that the tyrosine kinase inhibitor dasatinib, commonly used to treat chronic myeloid leukemia (CML)...

Prostate Cancer

Addition of Olaparib to Abiraterone in Metastatic Castration-Resistant Prostate Cancer: Overall Survival Results in the PROpel Trial

As reported by Fred Saad, MD, and colleagues in The Lancet Oncology, the final prespecified overall survival analysis of the phase III PROpel trial...

Skin Cancer

Previously Untreated Advanced Melanoma: Addition of Bempegaldesleukin to Nivolumab

In the phase III PIVOT IO 001 trial reported in the Journal of Clinical OncologyAdi Diab, MD, and colleagues found that the addition of bempegaldesleukin...

Gastroesophageal Cancer

Addition of First-Line Regorafenib to Nivolumab and Chemotherapy in Metastatic Esophageal Cancer

In a single-institution phase II study reported in The Lancet Oncology, Cytryn et al found that the combination of regorafenib...


Breast Cancer

Geoffrey J. Lindeman, MBBS, PhD, on Breast Cancer: Venetoclax and Fulvestrant in ER-Positive, HER2-Negative Disease

Solid Tumors

Pertuzumab/Trastuzumab Demonstrates Activity in Tissue-Agnostic Trial for Patients With HER2-Positive Tumors

Results from the phase II MyPathway basket trial found that the HER2-targeted therapies pertuzumab and trastuzumab demonstrated durable activity in patients with a wide variety of tumors marked by HER2 amplification or overexpression, although responses were limited in those with KRAS mutations....


Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Breast Cancer

Linda T. Vahdat, MD, MBA, on Triple-Negative Breast Cancer: Targeting the Tumor Microenvironment

Multiple Myeloma

APOLLO Trial: Addition of Subcutaneous Daratumumab to Pomalidomide/Dexamethasone in Previously Treated Patients With Multiple Myeloma

As reported in The Lancet Oncology by Meletios A. Dimopoulos, MD, and colleagues, the phase III APOLLO trial has shown significantly improved progression-free survival with the addition of subcutaneous daratumumab to pomalidomide/dexamethasone in patients with previously treated multiple myeloma....

Bladder Cancer

Pembrolizumab in BCG-Unresponsive High-Risk Non–Muscle Invasive Bladder Cancer: KEYNOTE-057

As reported in The Lancet Oncology by Arjun V. Balar, MD, and colleagues, the phase II KEYNOTE-057 trial showed that pembrolizumab produced enduring responses in a cohort of patients with high-risk non–muscle invasive bladder cancer unresponsive to bacillus Calmette-Guérin (BCG) who were ineligible ...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Breast Cancer

Nadia Harbeck, MD, PhD, on Luminal Breast Cancer: Prognostic Impact of Recurrence Score, Endocrine Response, and Other Factors

Breast Cancer

Adjuvant Trastuzumab Emtansine vs Paclitaxel/Trastuzumab in Stage I HER2-Positive Breast Cancer

In the phase II ATEMPT trial reported in the Journal of Clinical Oncology, Sara M. Tolaney, MD, MPH, and colleagues found that adjuvant trastuzumab emtansine (T-DM1) resulted in “excellent” invasive disease–free survival but did not reduce clinically relevant toxicity compared with...


Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...